Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134122 | 0.84 | CA2 (0.64) | PLA2G10PLA2G2ACA2TSHRHSD17B10 | |
| SCHEMBL6940225 | 0.83 | ITGB3 (0.73) | CA2CAMK2AAKR1B1TSHRABCC4 | |
| SCHEMBL69614 | 0.83 | CA2 (0.79) | CA2CAMK2AAKR1B1TSHRABCC4 | |
| SCHEMBL276932 | 0.81 | CA2 (0.62) | CA2CAMK2AAKR1B1TSHRABCC4 | |
| SCHEMBL23582819 | 0.81 | CA2 (0.67) | CA2CAMK2AAKR1B1TSHRABCC4 | |
| Hydrochloric Acid SCHEMBL8045403 | 0.81 | ITGB3 (0.71) | CA2CAMK2AAKR1B1TSHRABCC4 | |
| SCHEMBL7149167 | 0.80 | PLA2G10 (0.53) | PLA2G10PLA2G2ACA2TSHRHSD17B10 | |
| SCHEMBL9449832 | 0.80 | PLA2G10 (0.53) | PLA2G10PLA2G2ACA2TSHRHSD17B10 | |
| SCHEMBL7328644 | 0.80 | PLA2G10 (0.53) | PLA2G10PLA2G2ACA2TSHRITGB3 | |
| SCHEMBL28151928 | 0.80 | PLA2G10 (0.53) | PLA2G10PLA2G2ACA2TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-12 | — | — | US | disclosed |
| EP-4169925-B1 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-06-17 | — | — | US | disclosed |
| CN-119930589-A | Tricyclic compound, pharmaceutical composition and application | 广州国家实验室 | 2025-05-06 | — | — | CN | disclosed |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-4169925-A2 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | Novartis AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169925-A2 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | Novartis AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| EP-3810613-B1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-11 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7101882-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | disclosed |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ANCLIFF RACHAEL A | 2006-04-13 | — | — | US | disclosed |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| US-4855314-A | VASOCONTRICTORS, TREATMENT OF MIGRAINES, 3-(AMINO-ETHYL)-5-(PHENYL(ALKYL)-CARBONYL OR SULFONYL-AMINOALKYL SUBSTITUTED | GLAXO GROUP LIMITED (GB) | 1989-08-08 | — | — | US | disclosed |
| EP-0240096-A1 | Indole derivatives having a selective vasoconstrictor activity | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | PLA2G10 4785/4885PLA2G2A 4378/4885CA2 1347/4885 |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | PLA2G10 4279/4885PLA2G2A 4006/4885CA2 3973/4885 |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | NISCH, MYO3B, CYP11B2 | PLA2G10 4303/4885PLA2G2A 4292/4885CA2 2313/4885 |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | TPMT, SARS1, NLN | PLA2G10 4250/4885PLA2G2A 4057/4885CA2 4022/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | PLA2G10 3250/4885PLA2G2A 4055/4885CA2 551/4885 |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ARG1, ARG2, NFKBIA | PLA2G10 2854/4885PLA2G2A 2995/4885CA2 2579/4885 |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | CCR3, SCN1B, NR3C1 | PLA2G10 4864/4885PLA2G2A 4679/4885CA2 1816/4885 |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | PLA2G10 4121/4885PLA2G2A 3780/4885CA2 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.